On July 3, 2025, Simcere Pharmaceutical Group Limited’s innovative drug subsidiary, Simcere, announced that its next-generation VEGF-targeting antibody, Suvemcitug Injection, had received marketing approval from the National Medical Products Administration (NMPA). Suvemcitug is the first…
Recently, the National Medical Products Administration (NMPA) granted conditional approval for Olgotrelvir Sodium Capsules, a Class I innovative drug developed by Zhejiang ACEA Pharmaceutical Co., Ltd. ✨ The drug represents the world’s first dual-target oral…
The National Medical Products Administration (NMPA) has officially approved Firsekibart Injection, a Class 1 innovative biologic drug independently developed by Changchun GeneScience Pharmaceuticals Co., Ltd. ✨ This approval marks a major milestone in China’s treatment…
Nanjing Zenshine Pharmaceutical Co., Ltd. has announced that its independently developed antiviral drug, Sebaloxavir Marboxil tablets, has officially been approved for marketing by China’s National Medical Products Administration (NMPA). This approval marks a major milestone…
Suzhou Ascentage Pharma has achieved a significant milestone with the conditional approval of Lisaftoclax Tablets (brand name: Lishengtuo, research code: APG-2575) by the National Medical Products Administration (NMPA). ✨ This approval is for the treatment…
The National Medical Products Administration (NMPA) of China has granted conditional approval for Ifupinostat Hydrochloride for Injection (brand name: Beitelin), developed by Guangzhou BeBetter Medicine Co., Ltd. This Class 1 innovative drug is approved as…
The National Medical Products Administration (NMPA) has officially approved Zeprumetostat Tablets (brand name: Airuijing, development code: SHR2554), a Class 1 innovative drug independently developed by Jiangsu Hengrui Pharmaceuticals. ✨ The approval covers the treatment of…
As Artificial Intelligence (AI) continues to evolve, the global pharmaceutical industry is undergoing a profound transformation. AI is redefining innovative drug development and reshaping the pharmaceutical supply chain—from target identification to intelligent distribution ✨AI in…
The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) continues to drive medical progress in 2025, marking another transformative year for global drug development. The agency’s annual compilation of FDA…
Over the past decade, China pharmaceutical innovation has moved from “follower” to “parallel runner” and is now on the path to becoming a global “front-runner.” According to the Ten-Year Development Report on China Pharmaceutical Innovation…
DengYue Medicine — Chinese biotech soars to new heights as Innovent Biologics announces a landmark $11.4 billion collaboration with Japan’s Takeda Pharmaceutical. This deal ranks among the largest business development transactions in the sector’s history,…
As a Hong Kong drug wholesale distributor, we stay open to learning and closely track China’s progress in drugs and other new approvals, helping us anticipate trends and deliver timely, high-quality solutions for patients and…
